CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc.
(NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The
Regents of the University of California, the University of Vienna
and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners
of foundational intellectual property relating to CRISPR/Cas9
genome editing technology, were granted U.S. Patent No. 10,000,772
(“the ‘772 patent”) today by the U.S. Patent and Trademark Office
(USPTO). The patent covers methods of using optimized guide RNA
formats (including single guide and dual guide formats) in certain
environments, including eukaryotic cells (such as human, animal and
plant cells). The optimized formats modify the part of a guide RNA
that interacts with the CRISPR/Cas9 nuclease.
The ‘772 patent claims priority to a U.S. provisional
application, filed by UC on May 25, 2012. This application broadly
encompasses the CRISPR/Cas9 genome editing technology invented by
Jennifer Doudna’s and Charpentier’s research teams.
CRISPR Therapeutics, Intellia Therapeutics and Caribou
Biosciences issued the following joint statement on the grant of
the ‘772 patent: “We believe that the U.S. patent ‘772 granted
today covers the use of CRISPR/Cas9 genome editing with the RNA
guide formats that are widely used throughout the industry. We
anticipate this is the first of many patents that will be granted
to UC on this foundational CRISPR/Cas9 intellectual property.”
In addition to this granted U.S. patent, applications from this
patent estate have been found allowable in the United States and
also have issued in Europe, the United Kingdom, China, Japan and
various other countries worldwide. These patents cover the dual-
and single-guide RNA compositions of the widely adopted CRISPR/Cas9
genome editing technology and their uses in all environments,
including plant, animal and human cells as well as for use in human
therapeutics.
The ‘772 patent is not impacted by the USPTO’s decision to
terminate an interference between a separate UC patent application
and a patent application owned by the Broad Institute, Harvard
University and the Massachusetts Institute of Technology without
reaching a decision on which inventors were the first to invent the
use of CRISPR/Cas9 technology for genome editing. UC’s appeal of
that decision was heard on April 30, 2018 by the U.S. Court of
Appeals for the Federal Circuit, which will issue a decision in the
future.
For more information on the foundational CRISPR/Cas9
intellectual property, please
visit www.crisprcollective.com.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology and
rare diseases. To accelerate and expand its efforts, CRISPR
Therapeutics has established strategic collaborations with
leading companies including Bayer AG and Vertex
Pharmaceuticals. CRISPR Therapeutics AG is headquartered
in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations
based in Cambridge, Massachusetts, and business offices
in London, United Kingdom. For more information, please
visit www.crisprtx.com.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company focused on
developing proprietary, curative therapeutics using the CRISPR/Cas9
system. Intellia believes the CRISPR/Cas9 technology has the
potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases by replacing patients’ diseased cells.
The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
About Caribou Biosciences, Inc.Caribou is a
leading company in CRISPR genome engineering founded by pioneers of
CRISPR/Cas9 biology based on research carried out in the Doudna
Laboratory at the University of California, Berkeley. Caribou’s
tools and technologies provide transformative capabilities to
therapeutic development, agricultural biotechnology, industrial
biotechnology, and basic and applied biological research. For more
information, including information about obtaining research and
commercial licenses as well as collaborations,
visit www.cariboubio.com and follow the
Company @CaribouBio. “Caribou Biosciences” and the Caribou
logo are trademarks of Caribou Biosciences, Inc.
CRISPR Therapeutics’ Forward-Looking
Statement
Certain statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning: the timing of filing of
clinical trial applications and INDs, any approvals thereof and
timing of commencement of clinical trials, the intellectual
property coverage and positions of CRISPR Therapeutics, its
licensors and third parties, the sufficiency of CRISPR
Therapeutics’ cash resources and the therapeutic value,
development, and commercial potential of CRISPR/Cas9 gene editing
technologies and therapies. You are cautioned that forward-looking
statements are inherently uncertain. Although CRISPR Therapeutics
believes that such statements are based on reasonable assumptions
within the bounds of its knowledge of its business and operations,
the forward-looking statements are neither promises nor guarantees
and they are necessarily subject to a high degree of uncertainty
and risk. Actual performance and results may differ materially from
those projected or suggested in the forward-looking statements due
to various risks and uncertainties. These risks and uncertainties
include, among others: uncertainties regarding the intellectual
property protection for our technology and intellectual property
belonging to third parties; uncertainties inherent in the
initiation and completion of preclinical studies for CRISPR
Therapeutics’ product candidates; availability and timing of
results from preclinical studies; whether results from a
preclinical trial will be predictive of future results of the
future trials; expectations for regulatory approvals to conduct
trials or to market products; and those risks and uncertainties
described under the heading “Risk Factors” in CRISPR Therapeutics’
most recent annual report on Form 10-K, and in any other subsequent
filings made by CRISPR Therapeutics with the U.S. Securities
and Exchange Commission (SEC), which are available on the
SEC’s website at www.sec.gov. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made, and CRISPR Therapeutics undertakes no duty to update this
information unless required by law.
Intellia Therapeutics’ Forward-Looking
Statement
This press release contains “forward-looking statements” of
Intellia within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding the
intellectual property position and strategy of Intellia, its
licensors or other parties from which it derives rights, including
with respect to intellectual property regarding the CRISPR/Cas9
genome editing technology, or that of unrelated third parties;
Intellia’s ability to develop and commercialize CRISPR/Cas9-based
therapeutic products to address severe and life-threatening
diseases; and Intellia’s scientific, business and financial plans
and prospects. Any forward-looking statements in this press release
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, risks related to
Intellia’s ability to protect and maintain its position and rights
regarding its intellectual property portfolio, risks related to the
ability of Intellia’s licensors and other parties from which it
derives rights to protect and maintain their intellectual property
position and rights, the risk that third parties own or control
intellectual property necessary for Intellia to develop or
commercialize its product candidates, and the risk that any one or
more of Intellia’s product candidates will not be successfully
developed and commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K filed
with the Securities and Exchange Commission, as well as discussions
of potential risks, uncertainties, and other important factors in
Intellia’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Intellia Therapeutics undertakes no duty to
update this information unless required by law.
CRISPR Therapeutics Contacts
Media:Jennifer PaganelliWCG for CRISPR
Therapeutics+1 347-658-8290jpaganelli@wcgworld.com
Investors: Chris Erdman +1 617-686-1718
christopher.erdman@crisprtx.com
Intellia Therapeutics Contacts
Media: Jennifer Mound Smoter +1
857-706-1071 jenn.smoter@intelliatx.com
Investors: Lindsey Trickett +1
857-285-6211 lindsey.trickett@intelliatx.com
Caribou Biosciences Contact
Greg Kelley Feinstein Kean Healthcare +1 404-836-2302
gregory.kelley@fkhealth.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024